^
Association details:
| Biomarker: | RET fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | vepafestinib (TAS0953/HM06) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
Excerpt:
...- Locally advanced or metastatic non small cell lung cancer (NSCLC) patients with primary RET gene fusion and prior exposure to RET selective inhibitors...
Trial ID:
Source:
Title:
MA13.05 - TA0953/HM06, a Novel RET-specific Inhibitor Effective in Extracranial and CNS Disease Models of NSCLC with RETfusions
Published date:
07/12/2022
Excerpt:
TAS0953/HM06 was as effective as selpercatinib (10-30 mg/kg BID) and pralsetinib (15-30 mg/kg BID) at reducing growth of PDX models. TAS0953/HM06 (50 mg/kg BID) was superior to selpercatinib (10 mg/kg BID, p=0.0002; 25 mg/kg BID, p<0.0001) at inhibiting growth of ECLC5 brain xenograft tumors and increasing survival (selpercatinib 10 mg/kg BID, p=0.0012, selpercatinib 25 mg/kg BID, p=0.001, Log-rank test).Our data show that TAS0953/HM06 is effective at inhibiting growth in vitro and in vivo of preclinical models driven by RET fusions. TAS0953/HM06 was more effective than selpercatinib at decreasing CNS disease and extending survival, at a dose that produced comparable suppression of tumor growth in extracranial disease models. TAS0953/HM06 represents a promising new therapeutic option for patients with RET fusions including those with brain metastasis and those resistant to first-generation selective RET inhibitors.
Test:
